VRVertex Pharmaceuticals VRTX · NASDAQ
$501.95 +0.44% (+$2.21)
- Market cap
- $126.7B
- Enterprise value
- $122.5B
- P/E
- 28.8x
- Forward P/E
- 28.0x
- PEG
- -
- P/S
- 10.0x
- P/FCF
- 33.4x
- EV/EBITDA
- 22.5x
- ROIC
- 17.3%
- Bruto marža
- 86.0%
- Neto marža
- 34.9%
- Dividend yield
- -
- Payout ratio
- -
- Neto dolg/EBITDA
- -0.8x
- Beta
- 0.32
- Free float
- 99.8%
O podjetju
Vertex Pharmaceuticals (VRTX) is a leading biopharmaceutical company specializing in the development of drugs for the treatment of rare and severe diseases. Their primary focus is on the development of innovative therapies for patients with cystic fibrosis, a genetic disorder affecting the respiratory and digestive systems. Vertex Pharmaceuticals is at the forefront of gene therapy and molecular-based treatments. Vertex Pharmaceuticals stock is suitable for investors interested in the pharmaceutical sector and investments in the treatment of rare diseases. Add Vertex Pharmaceuticals stock to your watchlist on Bulios and be the first to receive updates on new medical breakthroughs and the development of therapies from this prominent company.
Sector
Healthcare
Industry
Biotechnology
CEO
Reshma Kewalramani
Employees
6,400
Headquarters
Boston
Vrednotenje
Je današnja cena primerna?
Rast in ocene
Ali podjetje raste in kaj sledi?
Donosnost in kakovost
Koliko prihodkov ostane in kako dobro podjetje uporablja kapital?
Finančno zdravje
Ali zmore svoj dolg?
Kapital in dividende
Kaj podjetje počne z zasluženim denarjem?
Analitiki
Kaj menijo strokovnjaki in ali se to spreminja?
Lastniki in insajderji
Kdo ima delnice in kaj počne vodstvo?
Segmenti
Kateri del podjetja raste?
Primerjava s konkurenco
Kako se primerja s podobnimi podjetji?
Cena in tveganje
Kako se delnica obnaša?
Izkazi
Vse številke